Lebdai S, Rahmène Azzouzi A, Delongchamps N B, Benchikh A, Campeggi A, Cornu J N, Dumonceau O, Faix A, Fourmarier M, Haillot O, Lukacs B, Mathieu R, Misrai V, Robert G, de La Taille A, Descazeaud A
Service d'urologie, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9, France.
Service d'urologie, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9, France.
Prog Urol. 2015 Jan;25(1):47-53. doi: 10.1016/j.purol.2014.09.049.
The French guidelines on the management of benign prostatic hyperplasia (BPH) have been published in 2012 by the LUTS committee of the French Urological Association. The aim of this study was to evaluate the impact of these guidelines on the BPH management by French urologists.
A questionnaire has been distributed by email to 1141 urologists members of the French Association of Urologists in November 2013.
We collected 222 responses (response rate: 19%). The guidelines have been read by 73% of the urologists. The guidelines were followed most of the time by 76% of them, 11% followed them systematically and 4.5% did not follow them. The new terminology was used by 28 to 52% according to the items. The symptoms were evaluated by the IPSS score (33%), by interrogatory alone (64%) or by neither of them (3%). Prostate volume was not systematically taken for account in the treatment strategy by 57% of the urologists. Sexual function was assessed systematically by 28% of the urologists, 11% used a questionnaire (IIEF: 92%). PSA was tested respectively by 70 and 51% of the urologists at the initial evaluation and the follow-up. After introduction of a monotherapy, 56% of the urologists evaluated the efficacy at 3 months.
The French guidelines for the management of benign prostatic hyperplasia (BPH) by the LUTS committee of the French Urological Association were well known and used by French urologists. Some improvements can be expected for the use of the IPSS score, the evaluation of the sexual function, and the use of the new terminology.
法国泌尿外科学会下尿路症状委员会于2012年发布了良性前列腺增生（BPH）管理的法国指南。本研究旨在评估这些指南对法国泌尿外科医生管理BPH的影响。
2013年11月通过电子邮件向1141名法国泌尿外科学会会员泌尿外科医生发放了问卷。
我们收集到222份回复（回复率：19%）。73%的泌尿外科医生阅读了该指南。76%的医生在大多数情况下遵循该指南，11%的医生系统遵循，4.5%的医生不遵循。根据项目不同，28%至52%的医生使用了新术语。33%的医生通过国际前列腺症状评分（IPSS）评估症状，64%的医生仅通过问诊评估，3%的医生两者都不使用。57%的泌尿外科医生在制定治疗策略时未系统考虑前列腺体积。28%的泌尿外科医生系统评估性功能，11%的医生使用问卷（国际勃起功能指数：92%）。在初始评估和随访时，分别有70%和51%的泌尿外科医生检测了前列腺特异性抗原（PSA）。采用单一疗法后，56%的泌尿外科医生在3个月时评估疗效。
法国泌尿外科学会下尿路症状委员会制定的法国良性前列腺增生（BPH）管理指南为法国泌尿外科医生所熟知并采用。在国际前列腺症状评分的使用、性功能评估和新术语的应用方面有望得到一些改进。
4级。
Zotero 插件